Immunogenicity of recombinant hepatitis B vaccine in thalassemic children

Indian Pediatrics

Volumn 36, Issue 5, 1999, Pages 498-501

  Sethi, G R ^a   Sharma, Sangeeta ^b   Sudha, S ^b   Rishi, R K ^b  

^a LOK NAYAK HOSPITAL   (India)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENIVAC HB; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HERBERBIOVAC HB; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD TRANSFUSION; CHILD; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; SEROCONVERSION; THALASSEMIA MAJOR;

BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 0033044847     PISSN: 00196061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. West DJ, Calandra GB, Ellis RW. Vaccination of infants and children against hepatitis B. Pediatr Clin North Am 1990; 37: 585-601.
2. Rasenack JWF, Schlayer H, Hettler F. Hepatitis B virus infection without immunological markers after open-heart surgery. Lancet 1995; 345: 355-357.
3. West DJ. Clinical experience with recombinant hepatitis B vaccine. Am J Infect Control 1989; 17: 172-180.
4. Greenberg DP. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. Pediatr Infect Dis J 1993; 12:438-445.
5. De Montalembert M, Costalgliola D, Lefrere JJ. Prevalence of markers for human immunodeficiency virus type 1, cytomegalovirus, and hepatitis B and C in multiply transfused thalassemia patients. Transfussion 1952; 32: 509-512.
6. Szmuness W, stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, et al. Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Eng J Med 1980; 303: 833-841.
7. Francis DP, Hadler SC, Thompson SE, Maynard JE, Ostrow DG, Altman N, et al. Prevention of hepatitis B with vaccine: Report from the Centers for Disease Control multi/ center efficacy trial among homosexual men. Ann Intern Med. 1982; 97: 362-366.
8. Lo KJ, Lee SD, Tsai YT, Wu TC, Chan CY, Chen GH, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in infants born to HBeAg-positive HBsAg-carrier mothers. Hepatology 1988; 8: 1647-1650.
9. Coursaget P, Yvonnet B, Chotard J, Sarr M, Vincelot P, N'doye R, et al. Seven year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet 1986; 2: 1143-1155.
10. Goh KT, Tan KL, Oon CJ, Chan SH. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: A four-year follow-up study. Bull WHO 1992; 70: 233-239.
11. Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: Comparison of three different vaccination schedules. J Infect Dis 1989; 160:766-769.
12. Matsaniotis N, Kattamis C, Laskari S, Liapaki K, Valassi-Adam H, Dionissopoulou E. Immune response to hepatitis B vaccine. Lancet 1981; i: 210.